Sign in to view content

Episode 10: Cytokines Levels and Response to Ranibizumab in DME with Dr. Rajeev Muni

Keyvan Koushan, MD, FRCSC

Audio
Published 2018

Related

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial
Andres Emanuelli, MD
Annual Meeting Talks
2023
Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more